In the last year, three therapies were approved by the FDA to significantly reduce relapses of neuromyelitis optica spectrum disorder, a rare autoimmune inflammatory disorder that can leave patients blind or paralyzed.
Between 4,000 and 15,000 patients in the United States are estimated to have neuromyelitis optica spectrum disorder (NMOSD). Patients can be affected by attacks of optic neuritis and transverse myelitis, which can result in partial recovery and remissions. Nearly half of patients experience permanent visual impairments.
In June 2019, the FDA approved Soliris (eculizumab, Alexion
Uncategorized